Celgene is paying Exscientia $25 million up front in a three-year discovery deal for three programs in oncology and autoimmunity.
Ovation.io reeled in $5 million in series A funding that it plans to use to accelerate lab deployment and expand other features.
The committee spoke out against clinical applications of human germline genome editing and called for stronger global governance of the field.
Canvassing more than 400,000 people in 8 months, Apple has finished an investigation of its smartwatch’s ability to detect irregular heart rhythms.
ExcepGen believes its approach could speed up discovery and even come up with protein targets previously thought to be undruggable.
Gottlieb challenged industry and academia to invest in new approaches and realign incentives to make clinical research more agile and effective.
Chinese biotech HitGen has inked a collaboration deal with India’s Sun Pharma Advanced Research arm to identify novel small molecule leads.
Charles River Labs has inked a licensing deal with drug discovery and development services provider Crown Bioscience for expanded access to the ZDSD rat model.
Reprocell is partnering with Medicines Discovery Catapult to focus on accelerating drug development for U.K. biotech firms.
NCI Director Ned Sharpless taking on the role of acting head of the FDA raises some intriguing possibilities for interagency cooperation.
